Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 600161 from our risk checks.
Beijing Tiantan Biological Products Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥24.30 |
52 Week High | CN¥27.27 |
52 Week Low | CN¥19.17 |
Beta | 0.31 |
11 Month Change | 1.21% |
3 Month Change | 14.35% |
1 Year Change | 10.12% |
33 Year Change | 2.17% |
5 Year Change | 65.77% |
Change since IPO | 223.17% |
Recent News & Updates
Recent updates
Shareholder Returns
600161 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -3.2% | -5.1% | -4.7% |
1Y | 10.1% | -22.4% | -17.5% |
Return vs Industry: 600161 exceeded the CN Biotechs industry which returned -22.4% over the past year.
Return vs Market: 600161 exceeded the CN Market which returned -17.5% over the past year.
Price Volatility
600161 volatility | |
---|---|
600161 Average Weekly Movement | 4.6% |
Biotechs Industry Average Movement | 6.2% |
Market Average Movement | 6.8% |
10% most volatile stocks in CN Market | 10.2% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600161 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600161's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1919 | 4,858 | Dao Xing Fu | www.tiantanbio.com |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include human albumin; intravenous human immunoglobulin; tetanus human immunoglobulin; rabies patient immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; and human prothrombin complex blood products.
Beijing Tiantan Biological Products Co., Ltd. Fundamentals Summary
600161 fundamental statistics | |
---|---|
Market cap | CN¥48.05b |
Earnings (TTM) | CN¥1.16b |
Revenue (TTM) | CN¥5.11b |
41.3x
P/E Ratio9.4x
P/S RatioIs 600161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600161 income statement (TTM) | |
---|---|
Revenue | CN¥5.11b |
Cost of Revenue | CN¥2.39b |
Gross Profit | CN¥2.72b |
Other Expenses | CN¥1.55b |
Earnings | CN¥1.16b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.59 |
Gross Margin | 53.20% |
Net Profit Margin | 22.79% |
Debt/Equity Ratio | 0% |
How did 600161 perform over the long term?
See historical performance and comparison